INS and metabolic dysfunction-associated steatohepatitis: Besides insulin, prognostic biomarkers for development of IR-related diseases (including T2D, DKD, CVD, NASH) as well as for patient selection for bariatric surgery and other insulin-sensitizing therapies are missing.